Cardarine (GW-501516) vs LGD-4033 (Ligandrol)

Mechanism

Cardarine is a selective peroxisome proliferator-activated receptor delta (PPARd) agonist, not a SARM (it does not bind the androgen receptor). PPARd activation in skeletal muscle upregulates genes for fatty acid oxidation (CPT1B, PDK4, ACOX1), shifting fuel substrate from glycolysis toward beta-oxidation, effectively increasing endurance capacity and fat utilization. It increases oxidative type I (slow-twitch) muscle fiber proportion, enhances mitochondrial biogenesis via PGC-1a coactivation, reduces circulating triglycerides and LDL, and increases HDL cholesterol. PPARd activation also reduces macrophage-mediated inflammation through NF-kB suppression.

Standard Dosing

Research indicates 10-20 mg daily orally for 8-12 weeks. Clinical trials (metabolic syndrome) used 2.5-10 mg/day.

Timing

Once daily, 1-2 hours before exercise for acute endurance benefit. Half-life approximately 16-24 hours. Consistent daily dosing.

Cycle Duration

8-12 week cycles. No HPG suppression, so PCT is not required. However, long-term safety is unknown and cycling is prudent.

Side Effects

• CANCER RISK: Accelerated tumor development in multiple organs observed in 2-year rodent study at all doses tested
• Headache
• Nausea
• Diarrhea
• Potential liver effects at high doses

Contraindications

• Active or history of cancer (CRITICAL — see notes on carcinogenicity)
• Pregnancy and breastfeeding
• Individuals under 21
• Liver disease

Best Stacking Partners

Mechanism

LGD-4033 is a potent nonsteroidal selective androgen receptor modulator with high AR binding affinity (Ki of approximately 1 nM). It demonstrates strong anabolic activity in muscle and bone with significantly reduced androgenic activity in prostate tissue, achieving an anabolic-to-androgenic ratio of approximately 10:1. LGD-4033 activates the AR with full agonist efficacy in muscle, upregulating the PI3K/Akt/mTOR pathway for protein synthesis and satellite cell recruitment. It produces dose-dependent suppression of SHBG, total testosterone, LH, and FSH, indicating significant HPG axis suppression even at low doses.

Standard Dosing

Research indicates 5-10 mg daily orally for 8-12 weeks. Phase 1 data showed significant lean mass gains at 1 mg/day.

Timing

Once daily, consistent timing. Half-life approximately 24-36 hours. No food timing requirements.

Cycle Duration

8-12 week cycles maximum. PCT strongly recommended after all but the shortest/lowest-dose cycles.

Side Effects

• Significant testosterone suppression (dose-dependent; occurs even at 1 mg/day)
• Suppressed SHBG, LH, and FSH
• Elevated liver enzymes / hepatotoxicity (case reports of cholestatic liver injury)
• HDL cholesterol suppression
• Headache
• Fatigue (late-cycle, from suppression)
• Water retention

Contraindications

• Androgen-sensitive cancers
• Pre-existing liver disease or elevated liver enzymes
• Pregnancy and breastfeeding
• Individuals under 21
• Athletes subject to WADA/anti-doping testing

Best Stacking Partners